NEW YORK (GenomeWeb News) – RNAi research services company Cenix BioScience said today it has signed an agreement to help CellCentric validate oncology drug candidates.
 
Dresden, Germany-based Cenix said it will combine high-throughput applications of RNAi-based gene silencing with high-content phenotypic analyses in cultured human cells to provide in vitro validation of several of CellCentric’s drug candidates.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.